Introduction {#S0001}
============

In the Western world, overnutrition has overcome undernutrition as a medical and societal problem.^[1](#CIT0001)--[3](#CIT0003)^ Beyond quantitative considerations, it appears that the consumption of ultra-processed food (rich in carbohydrates, sugars, salt, and fat) and soft drinks coupled to a relative scarcity of fruit and vegetables affects the majority of individuals even in high-income countries.^[4](#CIT0004)--[9](#CIT0009)^ Against this background, it is clear that the "normal diet" cannot be appreciated as a statistical norm (i.e., the diet of the average individual), but must be defined by public guidelines. Such guidelines, however, are overshadowed by political decisions and arguable observational epidemiology, meaning that they tend to differ among distinct countries.^[10](#CIT0010)^ Moreover, much of the preclinical research done with laboratory animals (mostly mice) is based on the comparison of different types of chemically non-defined regimens, meaning that the conclusions of such studies are often based on methodologically suboptimal approaches.^[11](#CIT0011),[12](#CIT0012)^ Indeed, in pharmacology, it is common practice to compare different experimental conditions that only differ with respect to the absence and the presence of a drug administered at different concentrations. This kind of rigor is absent from most nutritional studies, which ideally should be designed to test the effects of just one single macro- or micronutrient admixed as a chemically defined entity (*e.g*., sucrose, sodium chloride, cholesterol or specific vitamins).^[13](#CIT0013)^ Notwithstanding these limitations, it has become clear that the quantity and quality of nutrition plays a major role in determining the risk of cancer.^[14](#CIT0014)--[16](#CIT0016)^ Obesity is nowadays on the verge of beating tobacco as the principal avoidable risk factor for cancer.^[17](#CIT0017)--[19](#CIT0019)^ Along similar lines, a high variety of food that supplies all necessary micronutrients appears to be one of the principal factors that link high socioeconomic status with low disease risk.^[20](#CIT0020)^ Finally, multiple animal studies favor the idea that nutritional interventions may curb the progression of established cancers and improve the efficacy of anticancer treatments.^[21](#CIT0021)--[27](#CIT0027)^ These effects rely on the alteration of both oncometabolism (the anabolic and catabolic reactions that support oncogenesis, disease progression and resistance to treatment)^[28](#CIT0028),[29](#CIT0029)^ and immunometabolism (the metabolic features that regulate immune responses).^[30](#CIT0030)--[34](#CIT0034)^

Along the lines of our Trial Watch series,^[35](#CIT0035),[36](#CIT0036)^ we discuss the rationale for harnessing nutritional interventions in support of cancer therapy and the progress of recent clinical trials testing this therapeutic paradigm in cancer patients.

Anticancer effects of dietary interventions -- a cell-autonomous rationale {#S0002}
==========================================================================

Cancer cells, especially those studied in the laboratory, are characterized by an increase in anabolic reactions that give rise to the so-called Warburg effect, the fact that such cells tend to take up large amounts of glucose even in conditions in which oxidative phosphorylation can proceed in an unlimited fashion.^[37](#CIT0037)--[40](#CIT0040)^ This so-called 'aerobic glycolysis' allows glucose-derived carbon atoms to be used for biosynthetic reactions. Cancer cells also take up large amounts of amino acids through specific transporters in the plasma membrane, acquire increased amounts of proteins by pinocytosis, and even engulf their neighbors to cannibalize them.^[41](#CIT0041)--[43](#CIT0043)^ In an analogous fashion, cancer cells are avid consumers of lipids.^[44](#CIT0044)^ Given their anabolic appetite, it is not surprising that nutritional interventions designed to reduce tumor growth involve a reduction in macronutrient uptake. Thus, it has been shown in mice that short-term starvation (STS, meaning no food supply for 1--2 days with access to drinking water *ad libitum*) and alternate-day fasting (ADF, meaning the alternation of 1-day intervals with and without access to food) can reduce tumor progression.^[25](#CIT0025),[27](#CIT0027)^ Moreover, the specific depletion of proteins (as well as selected aminoacids) from nutrients can be harnessed to limit cancer growth.^[45](#CIT0045),[46](#CIT0046)^ One particular dietary intervention consists in a close-to-zero carbohydrate, low-protein, high-fat regimen that causes ketosis (*i.e*., the accumulation of 3-hydroxybutyrate, acetoacetate, and acetone, commonly known as ketone bodies).^[47](#CIT0047)^ Ketone bodies can be used by multiple tissues in replacement of glucose for energy metabolism.^[48](#CIT0048)^ In mice, multiple variants of ketogenic diet slowdown the progression of some cancer types and boost the efficacy of targeted therapeutic agents,^[49](#CIT0049),[50](#CIT0050)^ an effect that (at least in some setting) is linked to reduced insulin signaling.^[50](#CIT0050),[51](#CIT0051)^

One particular facet of these dietary interventions is their capacity to reduce the unwarranted side effect of genotoxic chemotherapy. For example, periodic fasting as well as the administration of a hypocaloric 'fasting-mimicking diet' (FMD) can enhance the efficacy of chemotherapy and, at the same time, limit chemotherapy-related weight loss and cardiotoxicity.^[27](#CIT0027),[52](#CIT0052)^ It has been theorized that transient calorie deprivation enhances the 'differential stress resistance' between chemotherapy-treated cancer cells (that would become more susceptible to the treatment) and normal, non-neoplastic cells (that would become more resistant to the toxic side effects to chemotherapy).^[53](#CIT0053)--[56](#CIT0056)^

Anticancer effects of dietary interventions -- an immunological rationale {#S0003}
=========================================================================

Over the past years, an ever-expanding body of evidence pleads in favor of the notion that the long-term success of chemotherapy, targeted therapy and radiotherapy requires the reestablishment of immunosurveillance.^[57](#CIT0057)^ In other words, the efficacy of antineoplastic treatments, which has long been thought to exclusively rely on cancer cell-autonomous effects, now turns out to require the induction of a protracted anticancer immune response to be efficient.^[58](#CIT0058)--[61](#CIT0061)^ Logically, the impact of dietary intervention on such immune-dependent antitumor effects has been studied in preclinical models.

In immunocompetent mice bearing transplantable tumors or carcinogen-induced breast cancer, chemotherapy with anthracyclines or oxaliplatin becomes more efficient if combined with shorts periods of starvation.^[22](#CIT0022),[24](#CIT0024)^ These combinatorial effects of chemotherapy and dietary intervention fully rely on a T lymphocyte-mediated anticancer immune response, meaning that they are lost upon T cell depletion.^[22](#CIT0022),[24](#CIT0024)^ Mechanistically, they have been linked to the induction of heme oxygenase-1 (HO-1) in cancer cells, the stimulation of autophagy in cancer cells (which would enhance their immunogenicity),^[62](#CIT0062)--[64](#CIT0064)^ a decrease in circulating insulin-like growth factor-1 (IGF1), as well as an increase in the frequency of common lymphocyte precursors (which would be immunostimulatory).^[22](#CIT0022),[24](#CIT0024),[65](#CIT0065)^ Whether such effects might involve major shifts in the gut microbiota has not been investigated thus far.^[66](#CIT0066),[67](#CIT0067)^ Moreover, the impact of dietary interventions on immunotherapies has been poorly explored, at least to our knowledge.^[68](#CIT0068),[69](#CIT0069)^ Available clinical evidence suggests that anti-melanoma immunotherapy with PD-1/PD-L1 blocking antibodies^[70](#CIT0070),[71](#CIT0071)^ is more efficient in obese than lean males,^[72](#CIT0072)^ casting doubts on the possibility to improve such therapies by brutal interventions designed to reduce overweight.

Published and ongoing clinical trials {#S0004}
=====================================

Very few trials testing the ability of nutritional interventions to boost the efficacy of cancer therapy have been reported in the peer-reviewed literature so far. A series of anecdotal cases of self-imposed starvation during chemotherapy suggested an improvement of subjective well-being suggestive of a reduction of side-effects.^[73](#CIT0073)^ In the same line, fasting for 48 h prior and 24 h after platinum-based chemotherapy proved its safety and feasibility in patients treated for diverse cancer types.^[74](#CIT0074)^ A Phase I trial confirmed that STS for 60 h (from 36 h prior to chemotherapy to 24 h post-chemotherapy) improves quality of life and fatigue in patients with gynecological cancer.^[75](#CIT0075)^ In breast cancer patients treated with neoadjuvant multimodal chemotherapy,^[76](#CIT0076)^ a 48-h starvation period (from 24 h before to 24 h after chemotherapy) reduced hematological toxicity and accelerated recovery from DNA damage in circulating leukocytes.^[77](#CIT0077)^ Women with ovarian and endometrial cancer following a ketogenic diet for 12 weeks reported higher physical and energy status compared to the control group, highlighting the feasibility of this regimen.^[78](#CIT0078)^ A special ketogenic diet, the so-called 'modified Atkins diet', reportedly reduces the progression of some advanced cancer patients, especially individuals experience robust weight reduction.^[79](#CIT0079)^ Similarly, a ketogenic regimen has been reported to induce objective responses in 6 out of 7 patients with recurrent glioblastoma that simultaneously were treated with the antiangiogenic drug bevacizumab.^[80](#CIT0080)--[82](#CIT0082)^ This effect appeared particularly strong in patients with stable ketosis.^[80](#CIT0080)^

The website ClinicalTrials.gov informs on multiple clinical trials that are either ongoing or completed, yet generally lack published information on the outcome ([Table 1](#T0001)). Many of these trials evaluate dietary interventions without further treatment (NCT01092247, NCT01865162, NCT02092753, NCT02286167, NCT03160599, NCT03194516, NCT03328858, NCT03785808, NCT00003367, NCT00020995, NCT00082732, NCT00444054, NCT01692587, NCT02129218, NCT02176902, NCT03221920, and NCT03679260). Such interventions include STS, intermediate fasting, FMD, multiple ketogenic and low-carbohydrate diets, low-fat/high-fiber regimens, protein-restrictive diets, low-calorie and low-glycemic regimens and a vegan diet in patients with a variety of advanced solid malignancies including glioblastoma (the most frequent indication), breast and gynecological cancer, melanoma, head and neck cancer, non-small cell lung carcinoma, ovarian cancer, pancreatic adenocarcinoma, and prostate cancer. Several trials also aim at investigating the combination of dietary interventions with (1) chemotherapy (NCT01175837, NCT02379585, NCT02126449, NCT02710721, NCT03162289, NCT03340935, NCT03595540, NCT03700437, NCT01419483, NCT01419587, NCT01975766, NCT02046187, NCT02302235, NCT02516501, NCT02939378, NCT02983942, NCT03075514, NCT03278249, NCT03451799, NCT03535701, NCT01802346, NCT02019979, and NCT02437474), (2) radiotherapy (NCT03340935, NCT01419483, NCT01419587, NCT01754350, NCT01975766, NCT02046187, NCT02302235, NCT02516501, NCT03075514, NCT03278249, NCT03451799, NCT01170299, and NCT02437474), (3) metformin, a medication for type II diabetes with pleiotropic effects on cancer cells^[83](#CIT0083)--[85](#CIT0085)^ (NCT03709147 and NCT02019979), (4) targeted-therapies (NCT02379585, NCT03595540 and NCT02768389), and (5) immunotherapies such as immune checkpoint blockers targeting PD-1^[86](#CIT0086),[87](#CIT0087)^ (NCT03595540 and NCT03700437) or the dendritic cells based-vaccine Sipuleucel-T^[88](#CIT0088),[89](#CIT0089)^ (NCT03329742). Interestingly, one study also sets to monitor anticancer immune responses induced by an FMD (NCT03454282).10.1080/2162402X.2019.1591878-T0001Table 1.Clinical trials employing diet for cancer therapy.Dietary interventionAdditional details (when available)NCTTherapeutic interventionCancer typePhaseStatusShort-term starvation24, 48, or 72 h of fasting or 48 h of FMDNCT00936364Platinum chemotherapyAdvanced solid tumors Recruiting 24, 36, or 48 h of fasting before chemotherayNCT01175837Chemotherapy Pilot studyCompleted STS 24 h before and 24 h after chemotherapyNCT01304251Docetaxel, Doxorubicin, CyclophosphamideBreast cancerPilot studyCompleted STS 24 h before and 24 h after chemotherapyNCT02379585Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, trastuzumab, pertuzumabBreast cancerPhase 1/2Terminated, has resultsFasting-mimicking dietFMD 36 to 48 h before and 24 h after chemotherapyNCT01954836ChemotherapyGynecologicalPilot studyCompleted FMDNCT02126449Neoadjuvant chemotherapyHER2-negative breast cancerPhase 2/3Terminated FMD 36 h before and 24 h after chemotherapyNCT02710721ChemotherapyProstate Recruiting FMD or vegan diet 36 to 48 h before and 24 h after chemotherapyNCT03162289ChemotherapyBreast and ovarian Recruiting FMD (low calorie, low protein, and low carboydrates) for 5 daysNCT03340935Standard therapiesAny malignancy except small-cell neuroendocrine tumors Recruiting 5 days of FMD 13 to 15 days before or 1 month after surgeryNCT03454282SurgeryBreast and melanoma tumors Recruiting FMD for 5 daysNCT03595540Chemo-, hormono-, targeted or immuno-therapies  Recruiting FMD 72 h before and 24 h after chemo-immunotherapyNCT03700437Carboplatin/pemetrexed and pembrolizumabNSCLC Not yet recruiting FMD for 5 daysNCT03709147MetforminAdvanced LKB1-inactive lung adenocarcinomaPhaseNot yet recruitingKetogenic dietKDNCT00575146BevacizumabRecurrent glioblastomaPhase 1Completed, has results KD for up to one yearNCT01092247NoHigh-grade glial tumors Unknown KD starts 2 days before chemoradiation and last at least during 5 weeks throughout the treatmentNCT01419483ChemoradiationPancreatic Terminated KD starts 2 days before chemoradiation and last at least during 5 weeks throughout the treatmentNCT01419587ChemoradiationCarcinoma, non-small cell lung cancer Terminated Energy-restricted KD starts after surgery and continues through radio and chemotherapy, ending 6 weeks after treatments completionNCT01535911Surgery followed by chemo- and radiotherapyBrain tumors Active, not recruiting KDNCT01716468NoMetastatic cancer Completed 2 cycles of 3 days calorie-restricted KD separated by 3 days fastingNCT01754350ReirradiationRecurrent glioblastoma Active, not recruiting KD with calorie restriction for 6 monthsNCT01865162NoRefractory/end-stage glioblastomaPhase 1Recruiting KD starts 2 days before chemoradiation and last at least during 5 weeks throughout the treatmentNCT01975766ChemoradiationHead and neck cancerPhase 1Terminated (poor accrual) KD starts after surgery and continues through radio and chemotherapy. A modified Atkins diet is implemented during the following month of chemotherapy.NCT02046187ChemoradiationGlioblastomaPhase 1/2Terminated KD or low glycemic and insulinemic diet for 20 weeksNCT02092753NoBreast cancer Completed Modified Atkins-based with intermittent fasting dietNCT02286167NoGlioblastoma Recruiting KD starts at the radiation initiation and continues 6 monthsNCT02302235Radiation and temozolomideGlioblastoma multiformePhase 2Recruiting Ketogenic breakfast after overnight fasting and before chemoradiation or KD throughout the entire period of chemoradiationNCT02516501Chemoradiation  Recruiting Low-carbohydrate vs low-fat diet before surgeryNCT02744079SurgeryBreast ER+ cancerPilot presurgical studyRecruiting Modified Atkins dietNCT02768389BevacizumabGlioblastomaEarly Phase 1Active, not recruiting KDNCT02939378Salvage chemotherapyRecurrent glioblastomaPhase 1/2Unknown KDNCT02983942MethotrexatePrimary central nervous system lymphomaPhase 1/2Not yet recruiting Modified KD or medium-chain triglyceride KD for 12 weeksNCT03075514Chemo- and/or radiotherapyGlioblastomaPilot studyActive, not recruiting Restricted calorie KDNCT03160599NoGlioblastoma multiforme Recruiting KD for 12 weeksNCT03171506NoOvarian and endometrial cancer Completed KD for 8 weeksNCT03194516NoProstate cancer Enrolling by invitation Modified Atkins KDNCT03278249Temozolomide and radiationMalignant glioma Recruiting KD for 7 days before surgeryNCT03285152SurgeryEndometrial cancer Recruiting KD for at least 1 yearNCT03328858NoBrain tumors Recruiting KD for 16 weeks througout chemoradiation treatmentNCT03451799Radiation and temozolomideGlioblastomaPhase 1Recruiting KD for 3 monthsNCT03535701PaclitaxelStage IV breast cancer Recruiting Low-carbohydrate high-fat ketogenic-type diet vs low-fat high low-glycemic carbohydrates dietNCT03785808NoLung cancer RecruitingSpecific low-nutrientLow-fat high-fiber dietNCT00003367NoProstate cancerPhase 3Completed Low-fat high-fiber diet for 3 weeksNCT00020995NoProstate cancerPhase 2Completed Low-fat high-fiber dietNCT00082732NoHormone-refractory prostate cancerPhase 1  Very low-carbohydrate diet for 28 daysNCT00444054NoAdvanced cancerPilot studyCompleted Low-fiber vs high-fiber dietNCT01170299RadiationGynecological, bladder, colorectal, or anal cancer Completed Protein-restrictive dietNCT01692587NoProstate cancer Completed Low-calorie diet from 3 days before to 2 days after the 12 weeks of chemotherapyNCT01802346ChemotherapyBreast, hormone-resistant, and recurrent prostate cancerPhase 2Recruiting Carbohydrate-restricted dietNCT02019979Metformin with platinum-based chemotherapyNon-squamous non-small cell lung cancerPhase 2Terminated, has results Low- or medium-glycemic diet for 12 weeksNCT02129218NoColon cancerPilot studyCompleted Low-fat omega-3 supplement diet for one yearNCT02176902NoProstate cancerPhase 2Recruiting Vegetarian vs vegan diets for 6 monthsNCT02437474Prescribed therapyAny cancer typePilot studyCompleted Very low-carbohydrate and high-fat dietNCT03221920NoColorectal adenocarcinoma Not yet recruiting Low protein diet from 1 week before to 10 days after treatmentNCT03329742Sipuleucel-TMetastatic castrate-resistant pancreatic cancer Recruiting Carbohydrate restricted diet for 6 monthsNCT03679260NoProstate cancerPhase 2Recruiting

It will be interesting to see whether any of these studies will document a clinical benefit linked to a specific nutritional intervention.

Concluding remarks {#S0005}
==================

Knowing the importance of nutrition and metabolism for human physiology, including the crosstalk between malignant and immune cells, it is not surprising that dietary interventions are attracting attention as safe means to limit tumor progression or restore disease control by the host immune system.^[90](#CIT0090)--[92](#CIT0092)^ While evidence from preclinical studies suggests that reducing total calorie intake (and perhaps specific macronutrients) may stimulate anticancer immunity, such evidence has not yet been obtained in clinical trials. Multiple trials testing these possibilities in patients with multiple types of cancer are on the way ([Table 1](#T0001)). Unfortunately, it will be difficult to compare results from different studies for at least two reasons that add upon the usual heterogeneity of clinical trials. First, dietary interventions are quite heterogeneous in nature.^[13](#CIT0013)^ Thus, the term 'ketogenic diet' may refer to distinct regimens differing in quantity, composition and even in the gross protein:fat ratio.^[93](#CIT0093)^ Second, the control arms of the studies, when exist, usually receive consulting on 'healthy dietary habits', which (1) is a non-standardized notion (with major cross-continental and cross-cultural divergences), (2) is usually not enforced, and (3) is extremely complex to monitor.

Thus, the studies listed in [Table 1](#T0001) might examine the differences between salutary (interventional) and poor (control) regimens, meaning that control regimens can be expected to have a negative impact on health status. For this reason, it will be important to standardize control diets, ensure compliance, and to define interventional regimens in an accurate fashion. This implies strict guidelines, their enforcement by connected objects and phone app-mediated control, as well as monitoring of multiple metabolic parameters (such as plasma metabolome, cytokine and hormone status, stool microbiota). Moreover, it will be important to monitor immune parameters in the tumor and the peripheral blood to gain insights into therapeutically relevant anticancer immune responses. Without this information, it will be difficult to obtain any useful knowledge on the impact of nutritional interventions on cancer therapy.
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